Rocket One Inc
hoththerapeutics.comWhat Do They Do?
Develops experimental therapies for cancer-related skin conditions and mast-cell diseases, as well as neurological, allergic and metabolic disorders.
10-K for FY2025, filed Mar 27, 2026We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on…View ↗
On February 1, 2020, we entered into a patent license agreement with The George Washington University (“GW”) pursuant to which GW granted…View ↗
We have obtained from North Carolina State University (“NC State”) an exclusive, worldwide, royalty bearing license to certain intellectual…View ↗
We intend to develop HT-ALZ for use in patients following the Section 505(b)(2) regulatory pathway of the FDA rules. Section 505(b)(2) of…View ↗
We have obtained an exclusive license from the University of Cincinnati to make, use, have made, import, offer for sale, and sell products…View ↗
On December 9, 2024, we entered into a license agreement with the Department of Veterans Affairs (the “VA”) pursuant to which the VA…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.8MView ↗
- ▲ +74% (Loss)
- vs −$2.2M in Q2 FY2025
-
Aug 11, 2026
Received a Nasdaq minimum bid-price deficiency notice
Nasdaq said Rocket One no longer met its minimum bid-price rule; trading continues while it has time to regain compliance.
Sources
8-K, filed Aug 11, 2026
On August 6, 2026, Rocket One Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that…View ↗
-
Jun 25, 2026
Regained Nasdaq minimum bid-price compliance
Nasdaq confirmed Rocket One had regained compliance with its minimum bid-price requirement.
Sources
8-K, filed Jun 25, 2026
On June 24, 2026, Rocket One Inc.. (the “Company”) received a letter from The Nasdaq Stock Market, LLC (“Nasdaq”) stating that because the…View ↗
Portfolio focus
The latest overview adds a program for obesity and related conditions; the older overview instead listed treatments for traumatic brain injury and stroke, acne and inflammatory bowel disease.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on…View ↗
HT-TBI injection is being developed as a ready-to-inject autoinjector for intramuscular injection to be used in both traumatic brain…View ↗
Retinoids, which include Vitamin A (retinol) and its analogues (both synthetic and metabolites), play a critical role in cell signaling and…View ↗
Loading...
